Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

Idelalisib

(2015) Arpita Shah et al.   ANNALS OF PHARMACOTHERAPY

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

(2015) C. Y. Cheah et al.   BLOOD

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

(2015) B.-S. Cho et al.   BLOOD

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

(2015) Stephen Mok et al.   BMC CANCER

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

(2015) Yutaka Fujiwara et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks

(2015) B.R. Achyut et al.   CANCER LETTERS

Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages

(2015) C. Frankenberger et al.   CANCER RESEARCH

Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer

(2015) D. L. Moughon et al.   CANCER RESEARCH

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2015) J. A. Califano et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

(2015) L. Zhai et al.   CLINICAL CANCER RESEARCH

The efficacy of oral adenosine A2Aantagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

(2015) Ruxandra Julia Vorovenci et al.   Expert Review of Neurotherapeutics

Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium

(2015) Letícia Scussel Bergamin et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited

(2015) Luke Boulter et al.   JOURNAL OF CLINICAL INVESTIGATION

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype

(2015) Meng Xu et al.   JOURNAL OF IMMUNOLOGY

Prostaglandin E2Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages

(2015) Milena Sokolowska et al.   JOURNAL OF IMMUNOLOGY

Hypoxia/Reoxygenation Inhibits P2Y11 Receptor Expression and Its Immunosuppressive Activity in Human Dendritic Cells

(2015) Stéphanie Chadet et al.   JOURNAL OF IMMUNOLOGY

α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors

(2015) Sanjay Bhattarai et al.   JOURNAL OF MEDICINAL CHEMISTRY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Natural and therapy-induced immunosurveillance in breast cancer

(2015) Guido Kroemer et al.   NATURE MEDICINE

Kinase inhibitors and monoclonal antibodies in oncology: clinical implications

(2015) Helen Gharwan et al.   Nature Reviews Clinical Oncology

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Pioneering government-sponsored drug repositioning collaborations: progress and learning

(2015) Donald E. Frail et al.   NATURE REVIEWS DRUG DISCOVERY

Tackling reproducibility in academic preclinical drug discovery

(2015) Stephen V. Frye et al.   NATURE REVIEWS DRUG DISCOVERY

Big opportunities for small molecules in immuno-oncology

(2015) Jerry L. Adams et al.   NATURE REVIEWS DRUG DISCOVERY

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

(2015) Nicholas Butowski et al.   NEURO-ONCOLOGY

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

(2015) William D. Tap et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models

(2015) Giovanni Luca Gravina et al.   PROSTATE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Radiotherapy and Immunogenic Cell Death

(2015) Encouse B. Golden et al.   SEMINARS IN RADIATION ONCOLOGY

Nitric oxide synthase in innate and adaptive immunity: an update

(2015) Christian Bogdan   TRENDS IN IMMUNOLOGY

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

(2015) Michael Lahn et al.   Drug Design Development and Therapy

Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model

(2015) Claudia Sorrentino et al.   Oncotarget

Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway

(2015) Manoj K. Kashyap et al.   Oncotarget

Autophagy is involved in TGF-β1-induced protective mechanisms and formation of cancer-associated fibroblasts phenotype in tumor microenvironment

(2015) Fang-Lan Liu et al.   Oncotarget

POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL

(2015) Edward Allan R. Sison et al.   Oncotarget

The efficacy of oral adenosine A2Aantagonist istradefylline for the treatment of moderate to severe Parkinson’s disease

(2015) Ruxandra Julia Vorovenci et al.   Expert Review of Neurotherapeutics

Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease

(2015) Robert A. Hauser et al.   JAMA Neurology

T H 2-Polarized CD4 + T Cells and Macrophages Limit Efficacy of Radiotherapy

(2015) Stephen L. Shiao et al.   Cancer Immunology Research

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial

(2015) Dick de Zeeuw et al.   Lancet Diabetes & Endocrinology

Increased sMICA and TGFβ1levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells

(2015) Stephan Klöß et al.   OncoImmunology

Mast cell/MDSC a liaison immunosuppressive for tumor microenvironment

(2015) Luca Danelli et al.   OncoImmunology

Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory

(2015) Junjie Wu et al.   OncoImmunology

CD73: A potential biomarker for anti-PD-1 therapy

(2015) Paul A Beavis et al.   OncoImmunology

Natural killer cell mediated immunosurveillance of pediatric neuroblastoma

(2015) Michaela Semeraro et al.   OncoImmunology

Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors

(2015) Diletta Di Mitri et al.   OncoImmunology

CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression

(2015) Nathalie Bonnefoy et al.   OncoImmunology

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

(2015) Nathalie Vigneron et al.   OncoImmunology

Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma

(2015) Yusuke Sato et al.   OncoImmunology

Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas

(2015) Brian Ahn et al.   OncoImmunology

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

(2015) Erika Vacchelli et al.   OncoImmunology

Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity

(2015) Daniel Gonnermann et al.   OncoImmunology

Kynurenine and uric acid levels in chronic myeloid leukemia patients

(2015) Vladimir Vonka et al.   OncoImmunology

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

(2015) Aitziber Buqué et al.   OncoImmunology

Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?

(2015) Guido Kroemer et al.   OncoImmunology

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

(2015) Jonathan Pol et al.   OncoImmunology

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy

(2015) Oana Draghiciu et al.   OncoImmunology

Consensus nomenclature for CD8+T cell phenotypes in cancer

(2015) Lionel Apetoh et al.   OncoImmunology

COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells

(2015) Ze-Lei Li et al.   OncoImmunology

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

(2015) Annie A Wu et al.   OncoImmunology

Idelalisib- a PI3Kδ targeting agent for B-cell malignancies

(2015) Yvonne G Hewett et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition

(2015) Edward Allan R. Sison et al.   Oncotarget

Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin

(2015) Chakrapani Tripathi et al.   Oncotarget

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

(2015) Hatem H. Soliman et al.   Oncotarget

Blockade of A2b Adenosine Receptor Reduces Tumor Growth and Immune Suppression Mediated by Myeloid-Derived Suppressor Cells in a Mouse Model of Melanoma

(2015) Raffaella Iannone et al.   NEOPLASIA

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia

(2014) J. R. Brown et al.   BLOOD

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma

(2014) I. W. Flinn et al.   BLOOD

A phase 1 study of the PI3K  inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

(2014) B. S. Kahl et al.   BLOOD

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

(2014) Akemi Kosaka et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.

(2014) Mario R. Mautino et al.   CANCER RESEARCH

Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

(2014) D. Mittal et al.   CANCER RESEARCH

Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions

(2014) Mousumi Majumder et al.   CANCER SCIENCE

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

(2014) Richard J. Kovacs et al.   Cardiovascular Toxicology

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

(2014) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2014) D. T. Weed et al.   CLINICAL CANCER RESEARCH

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

(2014) Jordi Rodon et al.   CLINICAL CANCER RESEARCH

Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs

(2014) P. P. Patwardhan et al.   CLINICAL CANCER RESEARCH

Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

(2014) Y. Mao et al.   CLINICAL CANCER RESEARCH

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages

(2014) P. Giannoni et al.   HAEMATOLOGICA

Potential for Developing Purinergic Drugs for Gastrointestinal Diseases

(2014) Fernando Ochoa-Cortes et al.   INFLAMMATORY BOWEL DISEASES

Adenosine Receptors: Expression, Function and Regulation

(2014) Sandeep Sheth et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

(2014) Jordi Rodón et al.   INVESTIGATIONAL NEW DRUGS

Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer

(2014) M. C. B. Tan et al.   JOURNAL OF IMMUNOLOGY

Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer

(2014) Jinpu Yu et al.   JOURNAL OF IMMUNOLOGY

Adenosine A2B receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells

(2014) Wakako Kaji et al.   JOURNAL OF TOXICOLOGICAL SCIENCES

Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression

(2014) A. J. Garcia et al.   MOLECULAR AND CELLULAR BIOLOGY

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

Organelle-specific initiation of cell death

(2014) Lorenzo Galluzzi et al.   NATURE CELL BIOLOGY

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2

(2014) Alastair J O'Brien et al.   NATURE MEDICINE

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Novel antiplatelet agents in acute coronary syndrome

(2014) Francesco Franchi et al.   Nature Reviews Cardiology

Current and emerging strategies for the prevention of graft-versus-host disease

(2014) Sung Won Choi et al.   Nature Reviews Clinical Oncology

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Mechanisms, impact and management of pain in rheumatoid arthritis

(2014) David A. Walsh et al.   Nature Reviews Rheumatology

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amino Acids and Immune Response: A Role for Cysteine, Glutamine, Phenylalanine, Tryptophan and Arginine in T-cell Function and Cancer?

(2014) Angelos K. Sikalidis   PATHOLOGY & ONCOLOGY RESEARCH

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

(2014) John C. Morris et al.   PLoS One

Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy

(2014) Marjolein Sluijter et al.   PLoS One

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment

(2014) G Bianchi et al.   Cell Death & Disease

Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation

(2014) Hongmei Fu et al.   Nature Communications

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

(2014) J. Bastid et al.   Cancer Immunology Research

Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling

(2014) Amitabha Chaudhuri   Frontiers in Immunology

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+T cells

(2014) Debbie C Strachan et al.   OncoImmunology

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

(2014) Lorenzo Galluzzi et al.   OncoImmunology

An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy

(2014) Mickaël Michaud et al.   OncoImmunology

Novel insights into the mechanism of action of lenalidomide

(2014) Michaela Semeraro et al.   OncoImmunology

Immunosurveillance of senescent cancer cells by natural killer cells

(2014) Alexandre Iannello et al.   OncoImmunology

Chemotherapy engages multiple pathways leading to IL-1β production by myeloid leukocytes

(2014) Christina Antonopoulos et al.   OncoImmunology

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy

(2014) Yuting Ma et al.   OncoImmunology

Tumor-infiltrating lymphocytes in breast cancer

(2014) Yasmin Issa-Nummer et al.   OncoImmunology

T cell immunosurveillance controls B lymphoma development

(2014) Axel Kallies   OncoImmunology

Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells

(2014) Silvana Morello et al.   OncoImmunology

Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide

(2014) Xin Chen et al.   OncoImmunology

Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages

(2014) Michael J Cavnar et al.   OncoImmunology

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

Overcoming immunosuppression to enhance a p53MVA vaccine

(2014) Nicola Hardwick et al.   OncoImmunology

Ménage à trois

(2014) Derek A Wainwright et al.   OncoImmunology

Trial Watch: Radioimmunotherapy for oncological indications

(2014) Norma Bloy et al.   OncoImmunology

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy

(2014) Irena Adkins et al.   OncoImmunology

Co-blockade of immune checkpoints and adenosine A2Areceptor suppresses metastasis

(2014) Arabella Young et al.   OncoImmunology

Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer

(2014) Panagiotis Balermpas et al.   OncoImmunology

AMD3100 protects from UV-induced skin cancer

(2014) Scott N Byrne et al.   OncoImmunology

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

(2014) Antonio M Grimaldi et al.   OncoImmunology

Notch and TGFβ

(2014) Hidetaka Ohnuki et al.   OncoImmunology

The hedgehog’s trick for escaping immunosurveillance

(2014) Jingwu Xie   OncoImmunology

Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients

(2014) Esther P M Tjin et al.   OncoImmunology

Immune checkpoints

(2014) Akhil Chawla et al.   OncoImmunology

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

The pancreatic cancer microenvironment: an immunologic battleground

(2014) Venu G Pillarisetty   OncoImmunology

Trial watch

(2014) Erika Vacchelli et al.   OncoImmunology

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

(2014) Shashi Gujar et al.   OncoImmunology

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+PD-L1+phenotype in prostate cancer

(2014) Lisa K Spary et al.   OncoImmunology

Trial watch: IDO inhibitors in cancer therapy

(2014) Erika Vacchelli et al.   OncoImmunology

Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

(2014) Encouse B Golden et al.   OncoImmunology

Consensus guidelines for the detection of immunogenic cell death

(2014) Oliver Kepp et al.   OncoImmunology

Trial Watch

(2014) Erika Vacchelli et al.   OncoImmunology

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

(2014) Minghui Li et al.   Journal for ImmunoTherapy of Cancer

Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors

(2013) Minoru Tanaka et al.   BIOORGANIC & MEDICINAL CHEMISTRY

8-BuS-ATP derivatives as specific NTPDase1 inhibitors

(2013) Joanna Lecka et al.   BRITISH JOURNAL OF PHARMACOLOGY

The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer

(2013) Polina Weitzenfeld et al.   CANCER LETTERS

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

(2013) J. Xu et al.   CANCER RESEARCH

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy

(2013) S. Mok et al.   CANCER RESEARCH

CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy

(2013) Yuting Ma et al.   CANCER RESEARCH

Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma

(2013) Lena-Maria Carlson et al.   CARCINOGENESIS

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

(2013) D. E. Sanford et al.   CLINICAL CANCER RESEARCH

Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction

(2013) Joshua J. Ziarek et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Inducers of immunogenic cancer cell death

(2013) Aleksandra M. Dudek et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes

(2013) Jeong-Hwan Yoon et al.   EMBO Molecular Medicine

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

(2013) Yuting Ma et al.   IMMUNITY

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly

(2013) Paolo Serafini   IMMUNOLOGIC RESEARCH

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Ketamine and Cancer Pain: The Reports of My Death Have Been Greatly Exaggerated

(2013) Kate Jackson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases

(2013) Hany Soliman et al.   JOURNAL OF CLINICAL ONCOLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Protective Role of the Inflammatory CCR2/CCL2 Chemokine Pathway through Recruitment of Type 1 Cytotoxic    T Lymphocytes to Tumor Beds

(2013) T. Lanca et al.   JOURNAL OF IMMUNOLOGY

Discovery of (R)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic Acid and Congeners As Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury

(2013) Michael C. Van Zandt et al.   JOURNAL OF MEDICINAL CHEMISTRY

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes

(2013) Timothy J. Sullivan et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

(2013) Stewart A. Factor et al.   MOVEMENT DISORDERS

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Adenosine receptors as drug targets — what are the challenges?

(2013) Jiang-Fan Chen et al.   NATURE REVIEWS DRUG DISCOVERY

Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase

(2013) N Weizman et al.   ONCOGENE

A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia

(2013) Jarkko Kalliomäki et al.   PAIN

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

(2013) Laura Ochoa-Callejero et al.   PLoS One

Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression

(2013) Mabel Ryder et al.   PLoS One

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases

(2013) M. Gil et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An Adenosine-Mediated Signaling Pathway Suppresses Prenylation of the GTPase Rap1B and Promotes Cell Scattering

(2013) E. Ntantie et al.   Science Signaling

CD39 and CD73 in immunity and inflammation

(2013) Luca Antonioli et al.   TRENDS IN MOLECULAR MEDICINE

Small Molecule Inhibitors of CXCR4

(2013) Bikash Debnath et al.   Theranostics

A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis

(2013) Xinrong Ma et al.   OncoImmunology

IFN-γ–Driven IDO Production from Macrophages Protects IL-4Rα–Deficient Mice against Lethality during Schistosoma mansoni Infection

(2012) Reena Rani et al.   AMERICAN JOURNAL OF PATHOLOGY

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Selectivity profiling of the novel EP2receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2receptor

(2012) Mark A Birrell et al.   BRITISH JOURNAL OF PHARMACOLOGY

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes

(2012) Maryam B. Lustberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

(2012) Eva Ellebaek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation

(2012) Feng Qian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells

(2012) M. Velasco-Velazquez et al.   CANCER RESEARCH

Importance of direct macrophage - Tumor cell interaction on progression of human glioma

(2012) Yoshihiro Komohara et al.   CANCER SCIENCE

Development of novel CXCR4-based therapeutics

(2012) Amnon Peled et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth

(2012) E. Schlecker et al.   JOURNAL OF IMMUNOLOGY

Inhibition of CD73 Improves B Cell-Mediated Anti-Tumor Immunity in a Mouse Model of Melanoma

(2012) G. Forte et al.   JOURNAL OF IMMUNOLOGY

Modulation of Host Natural Killer Cell Functions in Breast Cancer via Prostaglandin E2 Receptors EP2 and EP4

(2012) Dawn M. Holt et al.   JOURNAL OF IMMUNOTHERAPY

Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer

(2012) Astrid Drenckhan et al.   JOURNAL OF SURGICAL RESEARCH

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

(2012) Annemijn M Algra et al.   LANCET ONCOLOGY

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Cancer prevention by targeting angiogenesis

(2012) Adriana Albini et al.   Nature Reviews Clinical Oncology

Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer

(2012) Harald von Boehmer et al.   NATURE REVIEWS DRUG DISCOVERY

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

(2012) Ran Reshef et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival

(2012) Xiaoyun Liao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a Unique Small Molecule Modulator of CXCR4

(2012) Zhongxing Liang et al.   PLoS One

Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell Migration

(2012) John Karavitis et al.   PLoS One

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

(2012) L. Pilotte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges

(2012) Filomena de Nigris et al.   Recent Patents on Anti-Cancer Drug Discovery

Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling

(2012) Karen Knapp et al.   STRUCTURE

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway

(2012) Akio Ohta et al.   Frontiers in Immunology

Trial watch

(2012) Laura Senovilla et al.   OncoImmunology

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells

(2011) N. Obermajer et al.   BLOOD

In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist

(2011) KJ af Forselles et al.   BRITISH JOURNAL OF PHARMACOLOGY

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

(2011) Michael C. Schmid et al.   CANCER CELL

Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4

(2011) Dawn Holt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates

(2011) W. H. Fridman et al.   CANCER RESEARCH

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment

(2011) A. M. Lesokhin et al.   CANCER RESEARCH

PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment

(2011) N. Obermajer et al.   CANCER RESEARCH

COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells

(2011) M. Fujita et al.   CANCER RESEARCH

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

(2011) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Antibody Targeting of TGF-β in Cancer Patients

(2011) Scott Lonning et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression

(2011) Gennady G. Yegutkin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Adenosine promotes alternative macrophage activation via A2A and A2B receptors

(2011) Balázs Csóka et al.   FASEB JOURNAL

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

(2011) Long Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache

(2011) Maria Antonova et al.   JOURNAL OF HEADACHE AND PAIN

Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production

(2011) A. Clayton et al.   JOURNAL OF IMMUNOLOGY

Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase

(2011) D. R. Sharda et al.   JOURNAL OF IMMUNOLOGY

Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells

(2011) S. Ryzhov et al.   JOURNAL OF IMMUNOLOGY

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy

(2011) Qian Huang et al.   NATURE MEDICINE

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

(2011) Mark J. Anderton et al.   TOXICOLOGIC PATHOLOGY

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling

(2010) Ludovic Martinet et al.   BIOCHEMICAL PHARMACOLOGY

Synthesis, SAR and evaluation of [1,4′]-bipiperidinyl-4-yl-imidazolidin-2-one derivatives as novel CCR5 antagonists

(2010) David M. Rotstein et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function

(2010) Joris D Veltman et al.   BMC CANCER

Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer

(2010) Elaine T. Lam et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model

(2010) Saima Hassan et al.   INTERNATIONAL JOURNAL OF CANCER

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

(2010) H. K. Koblish et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

Apoptotic Cells Activate the "Phoenix Rising" Pathway to Promote Wound Healing and Tissue Regeneration

(2010) F. Li et al.   Science Signaling

Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis

(2009) Soo-Hong Min et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Spiropiperidine CCR5 antagonists

(2009) David M. Rotstein et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy

(2009) S. J. Priceman et al.   BLOOD

Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness

(2009) S. P. Hilchey et al.   JOURNAL OF IMMUNOLOGY

NF546 [4,4'-(Carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene- , '-diphosphonic Acid) Tetrasodium Salt] Is a Non-Nucleotide P2Y11 Agonist and Stimulates Release of Interleukin-8 from Human Monocyte-Derived Dendritic Cells

(2009) S. Meis et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

(2009) François Ghiringhelli et al.   NATURE MEDICINE

Imatinib and beyond—exploring the full potential of targeted therapy for CML

(2009) Alfonso Quintás-Cardama et al.   Nature Reviews Clinical Oncology

Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth

(2009) Stacy Porvasnik et al.   PROSTATE

Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease

(2009) Riccardo Polosa et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study

(2008) M. A. Villalona-Calero et al.   ANNALS OF ONCOLOGY

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction

(2008) S. M. Devine et al.   BLOOD

Adenosine receptors in regulation of dendritic cell differentiation and function

(2008) S. V. Novitskiy et al.   BLOOD

Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function

(2008) Namita Kundu et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma

(2008) Saby George et al.   Clinical Genitourinary Cancer

Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase

(2008) Alberto Molano et al.   IMMUNOLOGY LETTERS

Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors

(2008) Sanjeev Kumar et al.   JOURNAL OF MEDICINAL CHEMISTRY

A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer

(2008) Eugene H. Huang et al.   JOURNAL OF SURGICAL RESEARCH

Biomimetic synthesis of the IDO inhibitors exiguamine A and B

(2008) Matthew Volgraf et al.   Nature Chemical Biology

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

(2008) Gerd Fätkenheuer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates

(2008) Rao V. Kalla et al.   Purinergic Signalling

Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases)

(2008) Younis Baqi et al.   Purinergic Signalling

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice

(2007) Lorea Bueno et al.   EUROPEAN JOURNAL OF CANCER